News
The Analyst Verdict: argenx In The Eyes Of 12 Experts
18 Apr 24
Analyst Ratings
Wedbush Reiterates Outperform on argenx, Maintains $521 Price Target
18 Apr 24
News, Price Target, Reiteration, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on argenx, Maintains $451 Price Target
18 Apr 24
News, Price Target, Reiteration, Analyst Ratings
argenx Data Shows Evidence That VYVGART And VYVGART Hytrulo Deliver Transformative Results For Patients Suffering From Debilitating Autoimmune Diseases
16 Apr 24
News
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
10 Apr 24
Analyst Color, Biotech, Equities, News, Health Care, Price Target, Initiation, Analyst Ratings, Trading Ideas, General
HC Wainwright & Co. Maintains Buy on argenx, Maintains $451 Price Target
27 Mar 24
News, Price Target, Analyst Ratings
argenx Announces Plan To Continue The Development Of Efgartigimod Primary Sjogren's Disease
27 Mar 24
News
Key Takeaways From argenx Analyst Ratings
26 Mar 24
Analyst Ratings
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
26 Mar 24
News, Price Target, Small Cap, Markets, Analyst Ratings, Trading Ideas
Scotiabank Maintains Sector Perform on argenx, Raises Price Target to $408
26 Mar 24
News, Price Target, Analyst Ratings
argenx Receives Approval Of VYVGART In Japan For Adults With Primary Immune Thrombocytopenia
26 Mar 24
News
JMP Securities Reiterates Market Outperform on argenx, Maintains $471 Price Target
22 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
21 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
21 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
21 Mar 24
Biotech, Large Cap, News, Health Care, Movers, General
12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Mar 24
Movers
Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
21 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Truist Securities Maintains Buy on argenx, Raises Price Target to $440
5 Mar 24
News, Price Target, Analyst Ratings
Scotiabank Maintains Sector Perform on argenx, Raises Price Target to $402
1 Mar 24
News, Price Target, Analyst Ratings
JMP Securities Maintains Market Outperform on argenx, Raises Price Target to $471
1 Mar 24
News, Price Target, Analyst Ratings
Press releases
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
16 Apr 24
News, Press Releases
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
28 Mar 24
News, Press Releases
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
27 Mar 24
News, Press Releases
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
26 Mar 24
News, Press Releases
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
26 Mar 24
News, Press Releases
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
26 Mar 24
News, Press Releases
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
22 Mar 24
News, Press Releases
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
7 Mar 24
News, Press Releases
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
29 Feb 24
News, Press Releases
argenx to Present at Upcoming Investor Conferences
26 Feb 24
News, Press Releases
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
22 Feb 24
News, Press Releases
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
20 Feb 24
News, Press Releases